PCM
ANVS icon

Prelude Capital Management’s Annovis Bio ANVS Stock Holding History

Prelude Capital Management’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,770
Closed -$665K – 1714
2021
Q2 		$665K Sell
7,770
-3,278
-30% -$151K 0.02% 811
2021
Q1 		$308K Buy
+11,048
New +$236K 0.01% 1132

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's ANVS Position: Q3 2021 in Review

Prelude Capital Management sold out of Annovis Bio (ANVS) in Q3 2021, closing a stake of 7,770 shares — an estimated $665K sold.

Prelude Capital Management first reported a position in ANVS in Q1 2021 and held it in 2 quarters. The position peaked at $665K in Q2 2021. 38 funds tracked by Wall St. Rank hold ANVS as of Q3 2021.

  • Prelude Capital Management reported no remaining Annovis Bio position as of Q3 2021 after selling out during the quarter.
  • Prelude Capital Management sold 7,770 Annovis Bio shares in Q3 2021, an estimated $665K.
  • Prelude Capital Management first reported a position in Annovis Bio in Q1 2021 and held it in 2 quarters.
  • Prelude Capital Management's Annovis Bio position peaked at $665K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Annovis Bio as of Q3 2021.

Based on Prelude Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.